Information Provided By:
Fly News Breaks for December 18, 2019
ESPR
Dec 18, 2019 | 07:02 EDT
Citi analyst Joel Beatty believes Esperion Therapeutics' bempedoic acid is likely to be approved in Q1 of 2020 and that the shares should trade to $79 on the news. Bempedoic Acid is likely to be approved in both the U.S. and Europe, Beatty tells investors in a research note. The analyst maintains a Buy rating on Esperion shares with a $73 price target.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.